ArticleThe Journal of experimental medicine2005
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 1 synthesis or guideline pooled it, 425 citations in OpenAlex.
- The metabolic addiction of cancer stem cells.Frontiers in oncology · 2022Pooled it
- Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.Cancer immunology, immunotherapy : CII · 2017Trial
- Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.BMC cancer · 2011Trial
- The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN.Targeted oncology · 2011Trial
- CD4Oncoimmunology · 2026Article
- T cells are critical for pre-metastatic niche formation through the STAT3/IL-17 axis.Journal for immunotherapy of cancer · 2026Article
- Review on Photodynamic Therapy Combined with T-Cell Immunotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Mechanisms, Challenges, and Future Directions.Current treatment options in oncology · 2026Review
- Immunomodulation of UVB-induced regulatory T cells prevents the establishment of squamous cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- Temporal and context-dependent requirements for the transcription factor Foxp3 expression in regulatory T cells.Nature immunology · 2025Article
- Enhancing DC cancer vaccine by allogeneic MHC class II expression and Treg depletion.JCI insight · 2025Article
- Using major histocompatibility complex (MHC) II expression to predict antitumor response to CD4 + lymphocyte depletion.Scientific reports · 2025Article
- CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors.Journal for immunotherapy of cancer · 2025Article
- Article
- Depletion of conventional CD4Journal for immunotherapy of cancer · 2024Article
- T cell dysfunction and therapeutic intervention in cancer.Nature immunology · 2024Review
- Acquisition of suppressive function by conventional T cells limits antitumor immunity upon TScience immunology · 2023Article
- Review
- Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.Pharmaceutics · 2023Review
- Article
- Importance of TGFβ in Cancer and Nematode Infection and Their Interaction-Opinion.Biomolecules · 2022Review
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Tumor environment can be critical for preventing the immunological destruction of antigenic tumors. We have observed a selective accumulation of CD4(+)CD25(+) T cells inside tumors. In a murine fibrosarcoma L(d)-expressing Ag104, these cells made up the majority of tumor-infiltrating lymphocytes at the late stage of tumor progression, and their depletion during the effector phase, rather than priming phase, successfully enhanced antitumor immunity. We show here that CD4(+)CD25(+) T cells suppressed the proliferation and interferon-gamma production of CD8(+) T cells in vivo at the local tumor site. Blockade of the effects of IL-10 and TGF-beta partially reversed the suppression imposed by the CD4(+) cells. Furthermore, local depletion of CD4(+) cells inside the tumor resulted in a change of cytokine milieu and led to the eradication of well-established highly aggressive tumors and the development of long-term antitumor memory. Therefore, CD4(+)CD25(+) T cells maintained an environment in the tumor that concealed the immunogenicity of tumor cells to permit progressive growth of antigenic tumors. Our study illustrates that the suppression of antitumor immunity by regulatory T cells occurs predominantly at the tumor site, and that local reversal of suppression, even at a late stage of tumor development, can be an effective treatment for well-established cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.